| Aberrant hnRNP K expression: all roads lead to cancer M Gallardo, MJ Hornbaker, X Zhang, P Hu, C Bueso-Ramos, SM Post Cell Cycle 15 (12), 1552-1557, 2016 | 99 | 2016 |
| MYC protein expression is an important prognostic factor in acute myeloid leukemia M Ohanian, U Rozovski, R Kanagal-Shamanna, LV Abruzzo, S Loghavi, ... Leukemia & lymphoma 60 (1), 37-48, 2019 | 67 | 2019 |
| The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα JC Yalowich, X Wu, R Zhang, R Kanagasabai, M Hornbaker, BB Hasinoff Biochemical pharmacology 84 (1), 52-58, 2012 | 56 | 2012 |
| Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia MJL Aitken, F Ravandi, KP Patel, NJ Short Journal of Hematology & Oncology 14, 1-15, 2021 | 42 | 2021 |
| Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML S Herbrich, N Baran, T Cai, C Weng, MJL Aitken, SM Post, J Henderson, ... Journal for immunotherapy of cancer 9 (7), 2021 | 29 | 2021 |
| Emerging treatment options for patients with p53-pathway-deficient CLL MJL Aitken, HJ Lee, SM Post Therapeutic Advances in Hematology 10, 2040620719891356, 2019 | 27 | 2019 |
| Uncovering the role of RNA-binding protein hnRNP K in B-cell lymphomas M Gallardo, P Malaney, MJL Aitken, X Zhang, TM Link, V Shah, ... JNCI: Journal of the National Cancer Institute 112 (1), 95-106, 2020 | 26 | 2020 |
| Targeting the NRF2/HO-1 antioxidant pathway in FLT3-ITD-positive AML enhances therapy efficacy S Kannan, ME Irwin, SM Herbrich, T Cheng, LNL Patterson, MJL Aitken, ... Antioxidants 11 (4), 717, 2022 | 16 | 2022 |
| Early detection of transformation to BPDCN in a patient with MDS K Chamoun, S Loghavi, N Pemmaraju, M Konopleva, M Kroll, ... Experimental hematology & oncology 7, 1-5, 2018 | 16 | 2018 |
| Characterization of TRKA signaling in acute myeloid leukemia SM Herbrich, S Kannan, RM Nolo, M Hornbaker, J Chandra, ... Oncotarget 9 (53), 30092, 2018 | 15 | 2018 |
| p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL HJ Lee, M Gallardo, H Ma, X Zhang, CA Larsson, A Mejia, MJ Hornbaker, ... Blood cancer journal 6 (6), e434-e434, 2016 | 15 | 2016 |
| AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia SM Post, H Ma, P Malaney, X Zhang, MJL Aitken, PY Mak, VR Ruvolo, ... Haematologica 107 (6), 1311, 2022 | 14 | 2022 |
| Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome CB Benton, KS Chien, A Tefferi, J Rodriguez, F Ravandi, N Daver, ... Hematological oncology 37 (1), 96-102, 2019 | 13 | 2019 |
| Antileukemia effects of notch-mediated inhibition of oncogenic PLK1 in B-cell acute lymphoblastic leukemia S Kannan, MJL Aitken, SM Herbrich, LS Golfman, MG Hall, DH Mak, ... Molecular cancer therapeutics 18 (9), 1615-1627, 2019 | 10 | 2019 |
| Proteomic profiling of acute promyelocytic leukemia identifies two protein signatures associated with relapse FW Hoff, CW Hu, AA Qutub, Y Qiu, MJ Hornbaker, C Bueso‐Ramos, ... PROTEOMICS–Clinical Applications 13 (4), 1800133, 2019 | 8 | 2019 |
| Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered Runx1 splicing MJL Aitken, P Malaney, X Zhang, SM Herbrich, L Chan, O Benitez, ... NAR cancer 4 (4), zcac039, 2022 | 5 | 2022 |
| Two cases of possible familial chronic myeloid leukemia in a family with extensive history of cancer MJL Aitken, CB Benton, GC Issa, K Sasaki, M Yilmaz, NJ Short Acta haematologica 144 (5), 585-590, 2021 | 4 | 2021 |
| hnRNP K overexpression drives AML progression by altering pathways critical for myeloid proliferation and differentiation MJ Hornbaker, M Gallardo, X Zhang, H Ma, P Hu, JD Khoury, ... Blood, The Journal of the American Society of Hematology 128 (22), 744-744, 2016 | 4 | 2016 |
| The Eµ-hnRNP K murine model of lymphoma: novel insights into the role of hnRNP K in B-cell malignancies P Malaney, M Velasco-Estevez, P Aguilar-Garrido, MJL Aitken, LE Chan, ... Frontiers in immunology 12, 634584, 2021 | 3 | 2021 |
| Diverse landscape of TET2 variants in MDS and AML E Tallis, CB Benton, A Khan, R Assi, CD DiNardo, MJ Hornbaker, ... Blood 132, 1479, 2018 | 2 | 2018 |
